Literature DB >> 20694784

MS14, an Iranian herbal-marine compound for the treatment of multiple sclerosis.

Amrollah Ahmadi, Gholameza Habibi, Mehdi Farrokhnia.   

Abstract

MS14 is a natural herbal-marine drug, which has shown to slow down or halt the progression of multiple sclerosis (MS). This drug consists of 90% Penaeus latisculatus, 5% Apium graveolens, and 5% Hypericum perforatum L. Preclinically, the effects of MS14 have mostly been examined in an animal model of multiple sclerosis called experimental allergic encephalomyelitis (EAE). Clinical studies of the effects of MS14 in MS patients also showed that it could improve the patients' quality of life. MS14 is a safe drug in MS patients and might also be effective in the treatment of other neurodegenerative disorders with the same mechanisms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20694784     DOI: 10.1007/s11655-010-0270-1

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  7 in total

1.  Concentration of elements in serum of patients affected by multiple sclerosis with first demyelinating episode: a six-month longitudinal follow-up study.

Authors:  Andrea Visconti; Rodolfo Cotichini; Stefania Cannoni; Beatrice Bocca; Giovanni Forte; Anna Ghazaryan; Simone Santucci; Cristina D'Ippolito; Maria Antonietta Stazi; Marco Salvetti; Alessandro Alimonti; Giovanni Ristori
Journal:  Ann Ist Super Sanita       Date:  2005       Impact factor: 1.663

Review 2.  Herbal complement inhibitors in the treatment of neuroinflammation: future strategy for neuroprotection.

Authors:  Amod P Kulkarni; Laurie A Kellaway; Girish J Kotwal
Journal:  Ann N Y Acad Sci       Date:  2005-11       Impact factor: 5.691

3.  Oxidant stress in the pathogenesis of multiple sclerosis.

Authors:  M A Lutskii; I E Esaulenko
Journal:  Neurosci Behav Physiol       Date:  2007-03

Review 4.  Origin of fatigue in multiple sclerosis: review of the literature.

Authors:  D Kos; E Kerckhofs; G Nagels; M B D'hooghe; S Ilsbroukx
Journal:  Neurorehabil Neural Repair       Date:  2007-04-04       Impact factor: 3.919

5.  Trace element status in multiple sclerosis.

Authors:  D K Smith; E B Feldman; D S Feldman
Journal:  Am J Clin Nutr       Date:  1989-07       Impact factor: 7.045

6.  An Iranian herbal-marine medicine, MS14, ameliorates experimental allergic encephalomyelitis.

Authors:  Azita Parvaneh Tafreshi; Amrollah Ahmadi; Majid Ghaffarpur; Hossein Mostafavi; Hossein Rezaeizadeh; Bagher Minaie; Soghrat Faghihzadeh; Mohsen Naseri
Journal:  Phytother Res       Date:  2008-08       Impact factor: 5.878

Review 7.  Axonal damage in multiple sclerosis: a complex issue in a complex disease.

Authors:  Nikolaos Grigoriadis; Tamir Ben-Hur; Dimitrios Karussis; Ioannis Milonas
Journal:  Clin Neurol Neurosurg       Date:  2004-06       Impact factor: 1.876

  7 in total
  4 in total

1.  MS14, a Marine Herbal Medicine, an Immunosuppressive Drug in Experimental Autoimmune Encephalomyelitis.

Authors:  Abbas Ebrahimi Kalan; Jafar Soleimani Rad; Laya Kafami; Daryoush Mohamadnezhad; Amir Afshin Khaki; Amaneh Mohammadi Roushandeh
Journal:  Iran Red Crescent Med J       Date:  2014-07-05       Impact factor: 0.611

Review 2.  Complementary and alternative therapies in multiple sclerosis: a systematic literature classification and analysis.

Authors:  Goli Arji; Hossein Rezaeizadeh; Abdolrreza Naser Moghadasi; Mohammad Ali Sahraian; Mehrdad Karimi; Mojtaba Alizadeh
Journal:  Acta Neurol Belg       Date:  2022-01-21       Impact factor: 2.396

3.  MS14 down-regulates lipocalin2 expression in spinal cord tissue in an animal model of multiple sclerosis in female C57BL/6.

Authors:  Abbas Ebrahimi-Kalan; Jafar Soleimani Rad; Laya Kafami; Daryoush Mohammadnejad; Mehryar Habibi Roudkenar; Amir Afshin Khaki; Zeynab Aliyari Serej; Amaneh Mohammadi Roushandeh
Journal:  Iran Biomed J       Date:  2014

Review 4.  Marine-derived protein kinase inhibitors for neuroinflammatory diseases.

Authors:  Chong Ning; Hui-Min David Wang; Rong Gao; Yu-Chia Chang; Fengqing Hu; Xianjun Meng; Shi-Ying Huang
Journal:  Biomed Eng Online       Date:  2018-04-24       Impact factor: 2.819

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.